期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 217, 期 11, 页码 -出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20201181
关键词
-
资金
- National Institutes of Health [P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, R01AI078788, R37AI64003]
- George Mason University fast grant
- European ATAC Consortium grant [EC101003650]
- G. Harold and Leila Y. Mathers Charitable Foundation
- Robert S. Wennett postdoctoral fellowship
- National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program grant) [UL1 TR001866]
- Shapiro-Silverberg Fund for the Advancement of Translational Research
The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据